Effect of Intravenous Tranexamic Acid on Reduction of Blood Losses in Hip Fracture Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03211286 |
Recruitment Status : Unknown
Verified July 2017 by Alejandro Lizaur-Utrilla, PhD, MD, Elda University Hospital.
Recruitment status was: Recruiting
First Posted : July 7, 2017
Last Update Posted : January 31, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Studies have shown that hip fractures have a significant perioperative blood loss. Postoperative anaemia is associated with a higher morbidity and mortality.
Tranexamic acid is a safe and effective antifibrinolytic widely used to reduce blood loss in other forms of orthopaedic surgery and in traumatized patients. However, evidence on the effectiveness of TXA in lower extremity fracture care is more limited.
Hip fractures represent a common orthopedic injury in a fragile patient population that often necessitates post-operative blood transfusion thereby putting the patient at additional risk of complications.
The goal of this study is to assess if the use of tranexamic acid in patients with hip fractures will result in a reduction in blood losses and blood transfusion rates.
Our hypothesis is that by providing intravenous TXA at the time of surgery will decrease the amount of preoperative and intraoperative bleeding thereby leading to a decreased need for postoperative transfusion.
This a double blinded, placebo controlled, therapeutic trial in which the patients will be randomized to receive TXA or a placebo (saline solution). Treatment will be administered pre-operatively as well as at the time of surgical incision. The primary outcome will be need for blood transfusion. Secondary outcomes will include calculated perioperative blood loss, length of stay, and rate of thromboembolic events, and 90 day mortality.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hip Fractures Anemia | Drug: Tranexamic Acid Drug: Saline Solution | Phase 4 |
Candidates for the study will be consecutive patients with a diagnosis of hip fractures treated at our center. All patients with hip fracture meeting inclusion criteria will be recruited for enrollment into the study. Informed consent will be obtained from the patient prior to randomization.
At that time, each patient will be randomized into one of two groups by a independent staff using computer generated randomization and allocation concealment. The two patient groups will include:
- Study group: 1g of intravenous tranexamic acid at the time of surgical incision.
- Control group: placebo injection (saline solution) at the time of surgical incision.
Both patients and the treating surgeons will be blinded with regard to placebo vs. treatment until completion of the study.
Patients will be treated surgically with a long trochanteric femoral nail (TFN) or hemiarthroplasty.
Blood transfusion criteria will remain consistent with hospital standards (Hb<8 g/dL or >9 g/dL if symptomatic anemia). Total number of blood transfusions received will be documented upon patient discharge.
Deep vein thrombosis (DVT) prophylaxis will remain consistent with hospital standards (subcutaneous heparin from admission until 12 hours prior to surgery and beginning 6 hours after surgery). After discharge, .....
Patients will be followed at regular intervals (1mo, 3mo, and at least 6mo) and at each time point the patient will be asked to report any adverse events (DVT, PT, Stroke, myocardial infarction, infection, hospitalization). Diagnostic studies to assess for thromboembolic events (i.e. DVT, pulmonary embolism (PE), and stroke) will be ordered only if the patient develops clinical signs or symptoms that justify their use.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 110 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Patients will be treated surgically with a long trochanteric femoral nail (TFN) or hemiarthroplasty The two patient groups will include: 1) Study group treated with tranexamic acid at the time of surgical incision; 2) Control group treated with placebo injection (saline solution). Blood transfusion criteria will remain consistent with hospital standards. Deep vein thrombosis (DVT) prophylaxis will remain consistent with hospital standards (subcutaneous heparin from admission until 12 hours prior to surgery and beginning 6 hours after surgery). After discharge, ..... Patients will be followed at regular intervals (1mo, 3mo, and at least 6mo) and at each time point the patient will be asked to report any adverse events (DVT, PT, Stroke, myocardial infarction, infection, hospitalization). Diagnostic studies to assess for thromboembolic events (i.e. DVT, pulmonary embolism (PE), and stroke) will be ordered only if the patient develops clinical signs or symptoms that justify their use. |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Patients will be allocated into two groups based on randomized 20-block method by an independent assistant using computer generated randomization. Both patients and the treating surgeons will be blinded with regard to placebo vs. treatment until completion of the study |
Primary Purpose: | Treatment |
Official Title: | Effect of Intravenous Tranexamic Acid on Reduction of Blood Losses in Hip Fracture Patients. A Randomized, Controlled, Double-blind Study |
Actual Study Start Date : | January 30, 2018 |
Estimated Primary Completion Date : | December 31, 2018 |
Estimated Study Completion Date : | March 30, 2019 |

Arm | Intervention/treatment |
---|---|
Active Comparator: TXA group
Tranexamic acid, a single dose of 1 g intravenous diluted in 100 mL saline solution at the time of surgical incision
|
Drug: Tranexamic Acid
1 g of intravenous tranexamic acid in 100 mL of saline solution
Other Name: Saline solution Drug: Saline Solution saline solution 100 mL intravenous |
Placebo Comparator: Control group
Saline solution, 100 mL intravenous at the time of surgical incision
|
Drug: Saline Solution
saline solution 100 mL intravenous |
- blood transfusion rate [ Time Frame: Hospital stay, from admission to fourth day after surgery ]Number of patients needing blood transfusion
- Perioperative Blood Loss [ Time Frame: Hospital stay, from admission to fourth day after surgery ]Measurement by serial hemoglobin and hematocrit, and calculation of loss by mathematical formulas
- Infection rate [ Time Frame: 90 postoperative days ]surgical and medical (pneumonia, urinary tract, etc)
- Thrombotic events [ Time Frame: 90 postoperative days ]Deep Venous Thrombosis, Pulmonary Embolism, Myocardial Infarction, Stroke
- Mortality [ Time Frame: 90 postoperative days ]number of deaths

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- consecutive patients with a diagnosis of hip fractures treated at our hospital by any surgical procedureExclusion Criteria:
- Age over 60 years
Exclusion Criteria:
- ASA IV
- Concomitant fracture
- Refusal to receive blood products
- Preoperative anemia needing blood transfusion before surgery
- Severe comorbidity (cancer, severe pulmonary disease)
- Allergy for tranexamic acid.
- History of acute thromboembolic event (Deep Vein Thrombosis, Pulmonary Embolism, Stroke)
- Coagulopathy (INR > 1.4)
- Myocardial infarction in the previous 12 months
- Coronary stents
- Renal function impairment (serum creatinine > 2 mg/dL or creatinine clearance <30 mL/min),) or kidney transplant
- Platelet antiaggregant treatment in the week before surgery.
- Severe hepatic dysfunction (AST/ALT >60)
- History of hypercoagulability
- Acquired disturbances of color vision.
- Occurrence intraoperative surgical/medical/anesthetic complications

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03211286
Contact: Alejandro Lizaur-Utrilla, PhD, MD | +34 966989019 | lizaur1@telefonica.net |
Spain | |
Elda University Hospital | Recruiting |
Elda, Alicante, Spain, 03600 | |
Contact: Alejandro Lizaur-Utrilla, PhD, MD lizaur1@telefonica.net | |
Principal Investigator: Alejandro Lizaur-Utrilla, PhD, MD | |
Hospital Universitario de Elda | Not yet recruiting |
Elda, Alicante, Spain, 03600 | |
Principal Investigator: Blanca Gonzalez-Navarro, MD | |
Sub-Investigator: Francisco A. Miralles-Muñoz, MD | |
Sub-Investigator: Joaquin de-Juan-Herrero, PhD, MD |
Study Chair: | Alejandro Lizaur-Utrilla, PHD, MD | Orthopaedic Surgery Department, Elda University Hospital |
Responsible Party: | Alejandro Lizaur-Utrilla, PhD, MD, Head of Orthopaedic Surgery Department, Elda University Hospital |
ClinicalTrials.gov Identifier: | NCT03211286 |
Other Study ID Numbers: |
TXA-Hip July2017 |
First Posted: | July 7, 2017 Key Record Dates |
Last Update Posted: | January 31, 2018 |
Last Verified: | July 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Hip fracture Tranexamic acid Perioperative blood loss Blood Transfusion |
Hemorrhage Fractures, Bone Hip Fractures Wounds and Injuries Femoral Fractures Hip Injuries Leg Injuries Pathologic Processes |
Tranexamic Acid Pharmaceutical Solutions Antifibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Hemostatics Coagulants |